RecruitingPhase 2NCT05198323

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Studying Androgen insensitivity syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lumosa Therapeutics Co., Ltd.
Intervention
LT3001 Drug Product(drug)
Enrollment
66 target
Eligibility
18-90 years · All sexes
Timeline
20222026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05198323 on ClinicalTrials.gov

Other trials for Androgen insensitivity syndrome

Additional recruiting or active studies for the same condition.

See all trials for Androgen insensitivity syndrome

← Back to all trials